|Articles|December 29, 2015

CDC to Play Key Role in National Multidrug-Resistant TB Plan

On Dec. 23, 2015, the White House released the 

(MDR-TB), which is a crucial step to address MDR-TB, a growing public health threat that reflects missed opportunities to find, cure and prevent TB.

Despite being preventable and curable, TB ranks alongside HIV as the world’s leading cause of death from infectious disease. In 2014, nearly 10 million people became ill with TB, resulting in 1.5 million deaths. While the majority of MDR-TB cases are outside the U.S., TB respects no national borders – TB anywhere is TB everywhere.

MDR-TB is a strain of TB resistant to at least two of the first-line drugs used to treat TB, and is now is found in every country in the world. Even in countries with a low TB burden, like the United States, MDR-TB cases strain the public health system. The World Health Organization (WHO) estimates that there were nearly 500,000 MDR-TB cases globally in 2014. Compared to TB that is not drug resistant, MDR-TB takes a greater human and economic toll – it requires much longer treatment times with costlier drugs, can cause serious and permanent side effects, and significantly increases the risk of death. If left unchecked, 75 million additional people could die from MDR-TB by 2050, costing the global economy $17 trillion in lost productivity.

As a key implementer of the National Action Plan, the Centers for Disease Control and Prevention (CDC) supports TB programs throughout the United States and around the world to find, treat, cur, and prevent TB. The CDC says the National Action Plan will help the U.S. stay ahead of TB drug resistance with innovations in surveillance, outbreak detection, therapy for hard-to-treat cases, and a system to help address drug shortages.

Source: CDC


Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERIS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.